FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.34
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$21.46

05 Dec
2023

-0.260

OPEN

$21.54

-1.20%

HIGH

$21.87

321,650

LOW

$21.43

TARGET
$21.595 0.6% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
FPH: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) 40.2 xxx
DPS (cps) 37.7 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 55.2 xxx
Dividend Yield 1.7% xxx
Div Pay Ratio(%) 93.7% xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.26%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.71

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/12 - ex-div 16.59c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx39.5
DPS All xxxxxxxxxxxxxxx47.9
Sales/Revenue xxxxxxxxxxxxxxx1,447.4 M
Book Value Per Share xxxxxxxxxxxxxxx282.8
Net Operating Cash Flow xxxxxxxxxxxxxxx217.0 M
Net Profit Margin xxxxxxxxxxxxxxx15.76 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx14.28 %
Return on Invested Capital xxxxxxxxxxxxxxx13.45 %
Return on Assets xxxxxxxxxxxxxxx11.37 %
Return on Equity xxxxxxxxxxxxxxx14.28 %
Return on Total Capital xxxxxxxxxxxxxxx18.07 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-132.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx20 M
Long Term Debt xxxxxxxxxxxxxxx116 M
Total Debt xxxxxxxxxxxxxxx136 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx113 M
Price To Book Value xxxxxxxxxxxxxxx8.80

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx192.5 M
Capex % of Sales xxxxxxxxxxxxxxx13.30 %
Cost of Goods Sold xxxxxxxxxxxxxxx586 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx552 M
Research & Development xxxxxxxxxxxxxxx159 M
Investments - Total xxxxxxxxxxxxxxx65 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

30/11/2023

3

Neutral

-

-

Post Fisher & Paykel Healthcare's interim report, UBS is of the view the company remains poised for strong EPS growth from FY25 onwards, but with the shares considered fairly valued, the rating remains Neutral.

Price target has moved up to NZ$24.15 from NZ$23.15.

Stronger than forecast Homecare revenues helped the company releasing a slightly better-than-forecast financial performance.

On the other hand, revenue from the Hospital division disappointed and forecasts for this part of the group have been pared back.

FORECAST
UBS forecasts a full year FY24 dividend of 38.85 cents and EPS of 41.62 cents.
UBS forecasts a full year FY25 dividend of 43.47 cents and EPS of 53.65 cents.

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

FPH STOCK CHART

FNArena News on FPH

1
Australian Broker Call *Extra* Edition – Dec 07, 2023

10:04 AM - Daily Market Reports
2
November In Review: Equities Up As Bond Yields Slide

Dec 06 2023 - Australia
3
Rudi’s View: Bear&Bull Market To Continue (?) In 2024

Dec 06 2023 - Rudi's View
4
Australian Broker Call *Extra* Edition – Dec 04, 2023

Dec 04 2023 - Daily Market Reports
5
FNArena Corporate Results Monitor – 01-12-2023

Dec 01 2023 - Australia

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
2
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
3
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
4
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
5
ResMed: Finding A Base?

Aug 15 2023 - Technicals
6
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
7
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
8
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
9
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
10
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest